Candriam SCA’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

Candriam SCA’s Portfolio KYTH Stock Details KYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-64,476	Closed	-$4.86M	–	669
2015 Q2	$4.86M	Buy	+64,476	New	+$3.45M	0.1%	243
2015 Q1	–	Sell	-120,000	Closed	-$4.16M	–	675
2014 Q4	$4.16M	Buy	+120,000	New	+$4.19M	0.09%	263

Other funds holding KYTH

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Candriam SCA's KYTH Position: Q3 2015 in Review

Candriam SCA sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q3 2015, closing a stake of 64,476 shares — an estimated $4.86M sold.

Candriam SCA first reported a position in KYTH in Q4 2014 and held it in 2 quarters. The position peaked at $4.86M in Q2 2015. 143 funds tracked by Wall St. Rank hold KYTH as of Q3 2015.

Candriam SCA reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q3 2015 after selling out during the quarter.
Candriam SCA sold 64,476 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q3 2015, an estimated $4.86M.
Candriam SCA first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q4 2014 and held it in 2 quarters.
Candriam SCA's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $4.86M in Q2 2015.
143 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q3 2015.

Based on Candriam SCA's 13F filing for Q3 2015, filed 19 Oct 2015.